Invasive tracheobronchial aspergillosis in a patient with acute lymphoblastic leukemia (ALL) of PreB cells in late maintenance phase

Lucero O González Romero; Benigno A Jiménez Huerta; Adriana Rodríguez Valdés; José E Santos Hernández; Cuauhtli Q Acosta Rubio; Iván F Contreras Coronado Tovar; Rafael T Loaeza Rodríguez

2022, Number 4

<< Back Next >>

Enf Infec Microbiol 2022; 42 (4)

Invasive tracheobronchial aspergillosis in a patient with acute lymphoblastic leukemia (ALL) of PreB cells in late maintenance phase

González RLO, Jiménez HBA, Rodríguez VA, Santos HJE, Acosta RCQ, Contreras CTIF, Loaeza RRT

Full text

How to cite this article

Language: Spanish
References: 28
Page: 185-188
PDF size: 182.77 Kb.

ABSTRACT

A high risk of invasive aspergillosis has been observed in patients with hemato-oncological pathologies. Although chemotherapy schemes have decreased toxicity, there is still a high risk of immunosuppression.
Aspergillosis associated with tracheobronchial diseases includes saprophytic, allergic, and invasive tracheobronchial aspergillosis (ATBI) forms. The incidence of ATBI is around 6.9%, with a lethality between 58 and 90%.
Currently, voriconazole is the first-line treatment; an alternative is isavuconazole.
We present the case of a patient with acute lymphoblastic leukemia (ALL), with recurrent episodes of pneumonia manifested by hypoxemia and persistent fever, with a final diagnosis of invasive tracheobronchial aspergillosis.

REFERENCES

Routsi, C., Kaltsas, P., Bessis, E., Rontogianni, D., Kollias,S. y Roussos, C., “Airway obstruction and acuterespiratory failure due to Aspergillus tracheobronchitis”.Crit Care Med 2004; 32 (2): 580-582.
Alastruey, A., Mellado, E. y Cuenca, M., “Current sectionand species complex concepts in Aspergillus:recommendations for routine daily practice”. Ann N YAcad Sci, 2012; 1273: 18-24.
Mandell, G.L., Bennett, J.E. y Dolin, R., Enfermedadesinfecciosas: principios y práctica, 9ª ed., Barcelona, Elsevier,2020.
Kwon-Chung, K.J., “Aspergillus: diagnosis and descriptionof the genus”, en Vanden Bossche, H., Mackenzie,D.W.R. y Cauwenbergh, G. (eds.) Proceedings of theSecond International Symposium on Topics in Mycology,Amberes, Universidad de Amberes, 1987, pp. 11-21.
Krenke, R. y Grabczak, E.M., “Tracheobronchial manifestationsof Aspergillus infections”. Scientific WorldJournal 2011; 11: 2310-2329.
Denning, D.W., “Commentary: unusual manifestationsof aspergillosis”. Thorax, 1995; 50 (7): 812-813.
Kramer, M.R., Denning, D.W., Marshall, S.E. et al., “Ulcerativetracheobronchitis after lung transplantation: anew form of invasive aspergillosis”. Am Rev RespiratoryDis 1991; 144 (3 I): 552-556.
Denning, D.W., “Invasive aspergillosis”. Clin Infect Dis1998; 26 (4): 781-803.
Andresen, H., Venegas, P., Vega, C., Aravena, C. y Andresen,V. “Necrotizing tracheobronchial aspergillosis in an immunosuppressedpatient. Report of one case”, Rev Méd. Chile2015; 143 (4): 525-530.
Tissot, F., Agrawal, S., Pagano, L., Petrikkos, G., Groll,A.H., Skiada, A., Lass-Flörl, C., Calandra, T., Viscoli, C.y Herbrecht, R., “ecil-6 guidelines for the treatment ofinvasive candidiasis, aspergillosis and mucormycosisin leukemia and hematopoietic stem cell transplant patients”.Haematologica 2017; 102 (3): 433-444.
Patterson, T.F., Thompson, G.R. 3rd, Denning, D.W., Fishman,J.A., Hadley, S., Herbrecht, R., et al. “PracticeGuidelines for the Diagnosis and Management of Aspergillosis:2016. Update by the Infectious DiseasesSociety of America”, Clin Infect Dis 2016; 63 (4): e1-e60.
Ullmann, A.J., Aguado, J.M., Arikan-Akdagli, S., Denning,D.W., Groll, A.H., Lagrou, K., et al. “Diagnosis and managementof Aspergillus diseases: executive summary ofthe 2017 escmid-ecmm-ers guideline”. Clin Microbiol Infect2018; 24 Suppl 1: e1-e38.
Warris, A., Lehrnbecher, T., Roilides, E., Castagnola, E.,Brüggemann, R.J.M, Groll, A.H., “escmid-ecmm guideline:diagnosis and management of invasive aspergillosis inneonates and children”. Clin Microbiol Infect, 2019; 25(9): 1096-1113. doi: 10.1016/j.cmi.2019.05.019. Epub 31de mayo de 2019. pmid: 31158517.
Fernández, A., Lewis, R.E. y Kontoyiannis, D.P., “Howlong do we need to treat an invasive mold disease inhematology patients? Factors influencing duration oftherapy and future questions”, Clin Infect Dis, 2020; 71(3): 685-692.
Davoudi, S., Anderlini, P., Fuller, G.N. y Kontoyiannis,D.P., “A long-term survivor of disseminated Aspergillusand mucorales infection: an instructive case”. Mycopathologia,2014; 178: 465-470.
Parekh, B.S., Ou, C.Y., Fonjungo, P.N., Kalou, M.B.,Rottinghaus, E., Puren, A. et al., “Diagnosis of humanimmunodeficiency virus. Infection”, Clin Microbiol Rev, 2018; 32 (1): e00064-18.
Instituto Nacional de Estadística y Geografía (inegi), “Estadísticasa propósito del Día Mundial de la Lucha Contrael vih/sida (1 de diciembre)”, Comunicado de Prensanúm. 698/21, 29 de noviembre de 2021, 5 pp.
Fanales-Belasio, E., Raimondo, M., Suligoi, B. y Buttò,S., “hiv virology and pathogenetic mechanisms of infection:a brief overview”. Ann Ist Super Sanita 2010; 46(1): 5-14.
Deeks, S.G., Overbaugh, J., Phillips, A. y Buchbinder, S.,“hiv infection”. Nat Rev Dis Primers 2015; 1: 15035.
Braun, D.L., Kouyos, R.D., Balmer, B., Grube, C., Weber,R. y Günthard, H.F., “Frequency and spectrum ofunexpected clinical manifestations of primary hiv-1 infection”.Clin Infect Dis, 2015; 61 (6): 1013-1021.
Zandman-Goddard, G. y Shoenfeld, Y., “hiv and autoimmunity”.Autoimmun Rev 2002; 1 (6): 329-337.
Muema, D.M., Akilimali, N.A., Ndumnego, O.C., Rasehlo,S.S., Durgiah, R., Ojwach, D.B.A., et al. “Associationbetween the cytokine storm, immune cell dynamics,and viral replicative capacity in hyperacute hiv infection”.bmc Med 2020; 18 (1): 81.
Kreuzer, K.A. y Rockstroh, J.K., “Pathogenesis and pathophysiologyof anemia in hiv infection”. Ann Hematol1997; 75 (5-6): 179-187.
Español, I., Muñiz-Díaz, E., Margall, N., Rabella, N., Sambeat,M.A., Hernández, A. et al., “Serum thrombopoietinlevels in thrombocytopenic and non-thrombocytopenicpatients with human immunodeficiency virus (hiv-1) infection”.Eur J Haematol, 1999; 63 (4): 245-250.
Bettaieb, A., Oksenhendler, E., Duedari, N. y Bierling, P.,“Cross-reactive antibodies between hiv-gp120 and plateletgpiiia (cd61) in hiv-related immune thrombocytopenicpurpura”. Clin Exp Immunol, 1996; 103 (1): 19-23.
Semple, J.W., Rebetz, J., Maouia, A. y Kapur, R., “An updateon the pathophysiology of immune thrombocytopenia”.Curr Opin Hematol 2020; 27 (6): 423-429.
Semple, J.W., “Immune pathophysiology of autoimmunethrombocytopenic purpura”. Blood Rev, 2002; 16 (1): 9-12.
Secretaría de Salud, Subsecretaría de Prevención yPromoción de la Salud, Dirección General de Epidemiología,Sistema de Vigilancia Epidemiológica, “Informehistórico Día Mundial vih 2021”.